Computational Biology
| 3 min read
QDX and Prelude Therapeutics are developing drugs that selectively target the JAK2 V617F mutation, offering hope for patients with myeloproliferative neoplasms.
| 1 min read
Ongoing collaboration aims to bring new treatments for neurodegenerative conditions closer to patients.
| 8 min read
Jo Varshney explains how human-relevant models and mechanistic simulations are transforming early-stage drug discovery and development.
| 3 min read
From multiomic diagnostics to quantum computing, leading experts share the untapped opportunities that could reshape the future of therapeutics.
| 5 min read
Computational models are reshaping how therapies are discovered, tested, and optimized.
| 5 min read
Regulatory science is increasingly relying on modeling, simulation, and AI tools to accelerate drug development while maintaining safety and efficacy.
| 4 min read
A new platform may finally unlock the rules behind molecular glue degraders, turning chance discoveries into programmable therapeutics.
| 2 min read
Optibrium secures multi-million-pound financing package from Shawbrook to accelerate business growth
Proceeds will accelerate Optibrium’s product development and expand the global reach of its computational chemistry and AI-driven discovery technology
| 9 min read
A new app relies on smartphone cameras and algorithms to check for signs of neurodivergence in children.
Available on Demand
Advances in artificial intelligence enable high throughput compound profiling and cell viability analysis.
